Study S001069

A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06864026
Study type: INTERVENTIONAL
Phase: PHASE4
Masking: NONE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 200
Start: 2025-03-06
Primary completion: 2027-08
Lead sponsor: Eli Lilly and Company
Conditions: Psoriatic Arthritis; Overweight or Obesity
Interventions: DRUG:Tirzepatide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:I1F-MC-RHDE

Registered primary outcomes

Percentage of Participants Achieving Normalized Functioning Health Assessment Questionnaire - Disability Index (HAQ-DI) ≤0.5 at 12 Months of Therapy [12 Months]
Percentage of Participants Achieving at Least a 10% Weight Loss at 12 Months of Therapy [12 Months]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0000566	Glucagon-like peptide-1 receptor agonists in psoriasis and psoriatic arthritis: emerging evidence and future research opportunities. Ciancio G, Frontiers in immunology	2026	Other trial	PMID 42131335 DOI	cites ClinicalTrials.gov:NCT06864026